Impact of Mepolizumab on Airway Remodeling and Inflammation in Severe Eosinophilic Asthma
CHEST · 2026-04 · 169 (4) · 890-901
DOI: 10.1016/j.chest.2025.10.047 ↗Kurz gefasst
Fachartikel in der Zeitschrift CHEST, 2026-04. Verfasst von Camille Taillé und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pneumology, Allergology and Transplantation Department, AP-HP, Hôpital Bichat, Paris, France; Inserm, Unit 1149, Université Paris Cité, Paris, France…. Hauptthemen laut MEDLINE: Asthma, Airway Remodeling, Antibodies, Monoclonal, Humanized, Pulmonary Eosinophilia. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK.
Abstract (Originalsprache)
BACKGROUND: IL-5 is a key mediator of severe eosinophilic asthma (SEA) and also may contribute to airway remodeling. RESEARCH QUESTION: Can mepolizumab, an anti-IL-5 antibody, modify airway remodelling in adult patients with SEA? STUDY DESIGN AND METHODS: Thirty-seven patients who were eligible for mepolizumab were included prospectively. Mepolizumab 100 mg was administered subcutaneously every 4 weeks for 12 months. Bronchial biopsies and bronchoalveolar lavage (BAL) were performed at baseline, 6 months, and 12 months. Clinical and functional outcomes, airway remodeling, and inflammatory markers were assessed at each time point. RESULTS: At 12 months, mepolizumab was shown to improve asthma control and FVC before bronchodilation and reduce the number of exacerbations, oral corticosteroid courses, and hospitalizations. These clinical and functional improvements were associated with a reduction in reticular basement membrane thickness (P < 0.0001), airway smooth muscle (ASM) mass (P = .0066), and proliferating cell nuclear antigen-positive ASM cells (P < .0001) in the bronchial mucosa at both 6 and 12 months. BAL fluid showed reduced levels of tenascin-C at 6 and 12 months and of fibulin-1 at 12 months. Blood eosinophil counts decreased significantly (P < .0001), and eosinophils were almost completely depleted in BAL fluid (P = .023) at 12 months. Submucosal eosinophilia was reduced to a lesser extent (P = .063). INTERPRETATION: In addition to its antiinflammatory effects, mepolizumab also may attenuate structural airway changes in SEA, which could contribute to its clinical benefits. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT03797404; URL: www. CLINICALTRIALS: gov.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pneumology, Allergology and Transplantation Department, AP-HP, Hôpital Bichat, Paris, France; Inserm, Unit 1149, Université Paris Cité, Paris, France; Clinical Research Initiative in Severe Asthma: A Lever for Innovatio…
- Inserm, Unit 1149, Université Paris Cité, Paris, France.
- Department of Pathology, AP-HP, Hôpital Bichat, Paris, France.
- Pneumology, Allergology and Transplantation Department, AP-HP, Hôpital Bichat, Paris, France.
- Department of Statistics and Clinical Research, AP-HP, Hôpital Bichat, Paris, France.
Förderung
- GSK
Zitieren
APA
Taillé, C., Hamidi, F., Heddebaut, N., Poté, N., Le Guen, P., Le Brun, M., Roy, C., Dupont, A., & Létuvé, S. (2026). Impact of Mepolizumab on Airway Remodeling and Inflammation in Severe Eosinophilic Asthma. CHEST, 169(4), 890-901. https://doi.org/10.1016/j.chest.2025.10.047
Vancouver
Taillé C, Hamidi F, Heddebaut N, Poté N, Le Guen P, Le Brun M, et al. Impact of Mepolizumab on Airway Remodeling and Inflammation in Severe Eosinophilic Asthma. CHEST. 2026;169(4):890-901. doi:10.1016/j.chest.2025.10.047
BibTeX
@article{Taill2026,
author = {Taillé, Camille and Hamidi, Fatima and Heddebaut, Nicolas and Poté, Nicolas and Le Guen, Pierre and Le Brun, Mathilde and Roy, Carine and Dupont, Axelle and Létuvé, Séverine},
title = {Impact of Mepolizumab on Airway Remodeling and Inflammation in Severe Eosinophilic Asthma},
journal = {CHEST},
year = {2026},
volume = {169},
number = {4},
pages = {890--901},
doi = {10.1016/j.chest.2025.10.047}
}
EUVIMED